

# **ASX ANNOUNCEMENT**

### Friday 5 February 2021

## **Resignation of Director - Todd Barlow**

The Board of Directors of Palla Pharma Limited (ASX: PAL) ("the Company") wishes to announce that Mr Todd Barlow has resigned as a Director of the Company effective 4 February 2021.

Following the recent appointment of Mr Iain Ross to the Board, Mr Barlow has decided that after nearly six years as a Director he will step down from the Board to focus on his other commitments with Washington Soul Pattinson and Company.

The Board wishes to thank Mr Barlow for his contribution as a Director of the Company.

This announcement has been approved for release by the Board of Directors.

#### For more information please contact:

Simon Moore Chairman Palla Pharma Limited +61.3 9301 0800 Brendan Middleton Interim CEO Palla Pharma Limited +61.3 9301 0800 Adrian Mulcahy Investor Relations Market Eye +61 438 630 422 ir@pallapharma.com

#### **About Palla Pharma Limited:**

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient, and environmentally sustainable opiate manufacturing process based on a unique water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.